Cabotegravir Combined With Broadly Neutralizing Antibodies Maintains Undetectable HIV
ViiV Healthcare presented results today at this week’s CROI conference from its EMBRACE study demonstrating further evidence the combination of its broadly neutralizing antibodies (bNAb) N6LS, (VH3810109 or VH109), administered every 4 months, effectively maintained undetectable viral load when combined with long-acting cabotegravir. Results from the phase 2b study, EMBRACE, demonstrate that 96% of participants […]
Results from the LAPTOP Trial
At CROI 2025, Georg Behrens, MD, PhD, professor for T-Cell Immunology at Hannover Medical School, discussed the findings from the LAPTOP trial, a multi-center, European, open-label study that compared bictegravir (BIC) with darunavir (DRV) in therapy-naïve individuals with advanced HIV disease. This trial aimed to evaluate the efficacy and safety of an integrase inhibitor (INI)-based […]
Exploring Novel Dosing Strategies by Reducing Once Daily Biktarvy
Investigators found they could reduce the once-daily (OD) dosing of theantiretroviral therapy (ART) bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), (Biktarvy) from OD up to 3 weeks safely and effectively over a nearly a year time period.1 “In virally suppressed [people with HIV] PWH on [BIC/FTC/TAF] BETAF OD, the strategy of reducing the BETAF OD dose to 3W, 2W, […]
Gilead’s Once-Yearly Lenacapavir Formulations Show Sustained Efficacy for HIV PrEP in Phase 1 Study
At the CROI 2025, Moupali Das, MD, MPH, vice president of HIV prevention and virology pediatrics at Gilead Sciences, discussed new findings from a Phase 1 study investigating two formulations of once-yearly intramuscular (IM) lenacapavir for HIV pre-exposure prophylaxis (PrEP). These results, published simultaneously in The Lancet, present significant progress in the fight against HIV […]
Initial Findings from IMC-M113V Trial for HIV Functional Cure Strategy Shows Potential
Beatriz Mothe, MD, PhD, an infectious disease specialist at the IrsiCaixa AIDS Research Institute and attending physician at HUGTIP, Badalona, presented Immunocore’s early findings from the Phase 1/2 STRIVE trial on IMC-M113V, a novel HIV functional cure candidate at CROI 2025. The trial explores the potential of IMC-M113V, a T-cell receptor bispecific therapy designed to […]
HIV Education and Advocacy in an Age of Uncertainty
Federal clinical research funding freezes being carried out by the Trump Administration is affecting the HIV specialty. This means research looking at everything from HIV vaccines to new treatments remains paused without any timeline for when the funding might resume again. These freezes may also influence HIV prevention and clinical care. With concerns around these […]
HIV and Long COVID Insights from the RECOVER Program on Risk and Diagnosis
At CROI 2025, Kellie Hawkins, MD, assistant professor of medicine at the University of Colorado and attending infectious disease physician at Denver Health, discussed findings from the RECOVER Program, which explores the impact of HIV on Long COVID. The study examined the incidence of Long COVID in people living with HIV (PWH) and aimed to […]
Targeting Soluble gp120 to Combat Immune Dysfunction in People Living with HIV
At CROI 2025, we spoke with three researchers from Université de Montréal about the role of soluble gp120 (sgp120) in people living with HIV (PLWH). Mehdi Benlarbi, a PhD student explained how sgp120 may contribute to immune dysfunction, even in individuals with undetectable viral loads on ART. “We believe that soluble gp120, as a viral […]
Measles: An Old Foe Has Returned
Texas is experiencing its largest measles outbreak in 30 years and the Centers for Disease Control and Prevention’s (CDC) Epidemic Intelligence Service is providing support there. Here is an overview on testing, disease presentation, and vaccination, as well as commentary on the public health impact of vaccine hesitancy, and the unintended consequences of the immunization […]
Bivalent HIV Vaccine Induces Stronger T Cell Responses in People with HIV on ART
At CROI 2025, Nilu Goonetilleke, LLBHons, BScHons, PhD, associate professor at UNC School of Medicine, discussed The CM Study, a Phase 1 trial investigating the ChAdOx1 and MVA-based HIVconsvX vaccine. The vaccine uses viral vectors to express the HIVconsvX immunogens, Mosaic-1 and Mosaic-2, and aims to induce HIV-specific T-cell responses in people with HIV (PWH) […]
